Of molecular interactions, mice and mechanisms: New insights into Huntington's disease

Current Opinion in Neurology

Volumn 10, Issue 4, 1997, Pages 291-298

  Wellington, Cheryl L ^a   Hayden, Michael R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EXCITOTOXIN; PROTEIN; TRINUCLEOTIDE;

ANIMAL MODEL; APOPTOSIS; HUNTINGTON CHOREA; MOLECULAR INTERACTION; MOUSE; NONHUMAN; ONSET AGE; SHORT SURVEY; TRANSGENIC ANIMAL; TRINUCLEOTIDE REPEAT;

EID: 0030791305     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199708000-00003     Document Type: Short Survey

References (58)

1. Hayden MR: Huntington Disease. In Textbook of Internal Medicine, 2nd edn. Edited by Kelley WN. Philadelphia: J.B. Lippincott Co; 1991:2179-2181.
2. Brandt J, Bylsma FW, Gross R, Stine OC, Ranen NG, Ross CA: Trinucleotide repeat length and clinical progression in Huntington's disease. Neurology 1996, 46:527-531.
3. Graveland GA, Williams RS, Difiglia M: A golgi study of the human neostriatum: neurons and afferent fibers. J Comp Neurol 1985, 234:317-333.
4. Kowall NW, Ferrante RJ, Martin JB: Patterns of cell loss in Huntington's disease. Trends Neurol Sci 1987, 10:24-29.
5. Richardson EP Jr: Huntington's disease: some recent neuropathological studies. Neuropathol Appl Neurobiol 1990, 16: 451-460.
6. Beal MF, Lowall NW, Swartz KJ, Ferrante RJ, Martin JB: Differential sparing of somatostain-neuropeptide Y and cholinergic neurons following striatal excitotoxin lesions. Synapse 1989, 3:38-47.
7. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr: Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985, 44: 559-577.
8. Albin RL, Young AB, Penney JB: The functional anatomy of basal ganglia disorders. Trends Neurosci 1989, 12: 366-375.
9. Lanska DJ, Lanska MJ, Lavine L, Schoenberg BS: Conditions associated with Huntington's disease at death. A case-control study. Arch Neurol 1988, 45:878-880.
10. Richfield EK, Maguire-Zeiss KA, Vonkeman HE, Voorn P: Preferential loss of preproenkephalin versus preprotakykinin neurons from the striatum of Huntington's disease patients. Ann Neurol 1995, 38:852-861.
11. Tellez-Nagel I, Johnson AB, Terry RD: Ultrastructural and histochemical study of cerebral biopsies in Huntington's chorea. Adv Neurol 1973, 1:387-397.
12. Protera-Cailliau C, Hedreen JC, Price DL, Koliatsos VE: Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J Neurosci 1995, 15:3775-3787.
13. Thomas LB, Gates DJ, Richfield EK, O'Brien TF, Schweitzer JB, Steindler DA: DNA End Labeling (TUNEL) in Huntington's Disease and Other Neuropathological Conditions. Exp Neurol 1995, 133:265-272.
14. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fishbeck KH: Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991, 352:77-79.
15. 1A-voltage-dependent calcium channel. Nature Genet 1997, 15:62-69. This study describes the cloning and identification of the causative gene for spinocerebellar ataxia type-6.
16. La Spada AR, Roling DB, Harding AE, Warner CL, Spiegel R, Hausmanowa-Petrusewicz I, Yee W-C, Fischbeck KH: Meiotic stability and genotype-phenotype correlation of the trinucleotide repeat in X-linked spinal and bulbar muscular atrophy. Nature Genet 1992, 2:301-304.
17. Koide R, Ikeuchi T, Onodera O, Tanaka H, Igarashi S, Endo K, Takahashi H, Kondo R, Ishikawa A, Hayashi T et al.: Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nature Genet 1994, 6:9-13.
18. Komure O, Sano A, Nishino N, Yamauchi N, Ueno S, Konodoh K, Sano N, Takahashi M, Murayama N, Kondo I et al.: DNA analysis in hereditary dentatorubral-pallidoluysian atrophy: correlation between CAG repeat length and phenotypic variation and the molecular basis of anticipation. Neurology 1995, 45:143-149.
19. Nagafuchi S, Yanagisawa H, Sato K, Shirayama T, Ohsaki E, Bundo M, Takeda T, Tadokoro K, Kondo I, Murayama N et al.: Dentatorubral and pallidoluysian atrophy expansion of an unstable CAG trinucleotide on chromosome 12p. Nature Genet 1994, 6:14-18.
20. Takiyama Y, Igarashi S, Rogaeva Ea, Endo K, Rogaev Ei, Tanaka H, Sherrington R, Sanpei K, Liang Y, Saito M et al.: Evidence for intergenerational instability in the CAG repeat in the MJD1 gene and for conserved haplotypes at flanking markers amongst Japanese and Caucasian subjects with Machado-Joseph disease. Hum Mol Genet 1995, 4:1137-1146.
21. Maciel P, Gaspar C, Destefano AL, Silveira I, Coutinho P, Radvany J, Dawson DM, Sudarsky L, Guimaraes J, Loureiro JEL et al.: Correlation between CAG repeat length and clinical features in Machado-Joseph disease. Am J Hum Genet 1995, 57:54-61.
22. Maruyama H, Nakamura S, Matsuyama Z, Sakai T, Doyu M, Sobue G, Seto M, Tsujihata M, Oh IT, Nishio T et al.: Molecular features of the CAG repeats and clinical manifestation of Machado-Joseph disease. Hum Mol Genet 1995, 4:807-812.
23. Jodice C, Malaspina P, Persichetti F, Novelletto A, Spadaro M, Giunti P, Morocutti C, Terrenato L, Harding AE, Frontali M: Effect of trinucleotide repeat length and parental sex on phenotypic variation in spinocerebellar ataxia 1. Am J Hum Genet 1994, 54:959-965.
24. Ranum LPW, Chung M-Y, Banfi S, Bryer A, Schut LJ, Ramesar R, Duvick LA, McCall AE, Subramony SH, Goldfarb L et al.: Molecular and clinical correlations in spinocerebellar ataxia type 1 (SCA1): evidence for familial effects on the age of onset. Am J Hum Genet 1994, 55:244-252.
25. Brinkman RR, Mezei MM, Thielmann J, Almqvist E, Hayden MR: The likelihood of being affected with Huntington disease by a particular age for a specific CAG size. Am J Hum Genet 1997, 60:1202-1210. This study describes Kaplan Meier survival analysis to predict the age of onset of HD for individuals with CAG sizes ranging from 39 50 repeats. The inclusion of at-risk individuals permits discrete survival curves to be drawn for each CAG sizes. The implications for predictive testing are discussed.
26. Kalchman MA, Koide HB, McCutcheon K, Graham RK, Nichol K, Nishiyama K, Lynn FC, Kazemi-Esfarjani P, Metzler M, Goldberg YP et al.: HIP1, a human homolog of S. cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain. Nature Genet 1997, 16:44-53. The authors use the yeast two-hybrid screen to clone HIP1, a novel brain-enriched protein associated with the cytoskeleton.
27. Wanker EE, Rovira C, Scherzinger E, Hasenbank R, Walter S, Tait D, Colicelli J, Lehrach H: HIP1: a huntingtin interacting protein isolated by the yeast two-hybrid system. Hum Mol Genet 1997, 6:487-495. The authors use the yeast two-hybrid screen to clone HIP1, a novel brain-enriched protein associated with the cytoskeleton.
28. Koshy B, Matilla T, Burright EN, Merry DE, Fischbeck KH, Orr HT, Zoghbi HY: Spinocerebellar ataxia type-1 and spinobulbar muscular atrophy gene products interact with glyceraldehyde-3-phosphate dehydrogenase. Hum Mol Genet 1996, 5:1311-1318. This study uses yeast two-hybrid analysis to demonstrate an interaction between the spinocerebellar ataxia type-1 and SBMA gene products with GAPDH.
29. Kalchman MA, Graham RK, Xia G, Koide HB, Hodgson JG, Graham KC, Goldberg YP, Gietz RD, Pickart CM, Hayden MR: Huntingtin is ubiquitinated and interacts with a specific ubiquitin conjugated enzyme. J Biol Chem 1996, 271:19385-19394. Identification of HIP2, a HIP with a known role in protein degradation, is presented.
30. Burke JR, Enghild JJ, Margin ME, Joy Y-S, Myers RM, Roses AD, Vance JM, Strittmatter WJ: Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nature Genet 1996, 2:347-350. The authors demonstrate a direct interaction between glyceraldehyde phosphate dehydrogenase and expanded polyglutamine tracts in the proteins for HD and dentatorubralpallidoluysian atrophy using biochemical methods.
31. Nasir S, Floresco SB, O'Kusky JR, Diewert VM, Richman JM, Zeisler J, Borouski A, Marth JD, Phillips AG, Hayden MR: Targeted disruption of the murine Huntington disease gene results in early post-implantation embryonic lethality and behavioural and morphological abnormalities in heterozygotes. Cell 1995, 81:811-823.
32. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP: Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506. The authors describe an intriguing neurological phenotype in mice transgenic for the first exon of Hdh with very large CAG lengths. The phenotype of these mice includes motor abnormalities such as tremor and involuntary movements, drastic weight loss and reproductive anomalies, but does not include specific neurodegeneration.
33. Li X-J, Li S-H, Sharp AH, Nucifora FC Jr, Schilling G, Lanahan A, Worley P, Snyder SH, Ross CA: A huntingtin-associated protein enriched in brain with implications for pathology. Nature 1995, 378:398-402.
34. Li X-J, Sharp AH, Li S-H, Dawson TM, Snyder SH, Ross CA: Huntingtin-associated protein (HAP1): discrete neuronal localization resemble those of neuronal nitric oxide synthase. Proc Natl Acad Sci U S A 1996, 93:4839-4844.
35. Andrade MA, Bork P: HEAT repeats in the Huntington's disease protein. Nature Genet 1995, 11:115-116.
36. Holtzman DA, Yang S, Drubin DG: Synthetic-lethal interactions identify two novel genes, SLA1 and SLA2, that control membrane cytoskeleton assembly in Saccharomyces cerevisiae. J Cell Biol 1993, 122:635-644.
37. Munn AL, Stevenson BJ, Geli MI, Reizman H: end5, end 6, and end 7: mutations that cause actin delocalization and block the internalization step of endocytosis in Saccharomyces cerevisiae. Molec Biol Cell 1996, 6:1721-1742.
38. +-ATPase of Saccharomyces cerevisiae. J Biol Chem 1995, 270:6815-6823.
39. Hodgson JG, Smith DJ, McCutcheon K, Koide HB, Nishiyama K, Dinulos MB, Stevens ME, Bissada N, Nasir J, Kanazawa K et al.: Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype. Hum Mol Genet 1996, 5:1875-1885. This study demonstrates the utility of YAC transgenic approaches to the development of animals models for disorders associated with polyglutamine expansion. The authors show that despite differences to the murine protein, human huntingtin is expressed in a identical manner to that of the murine protein and can rescue the embryonic lethal phenotype in mice homozygous for a targeted disruption in murine Hdh exon 5.
40. Snider WD, Johnson EM: Neurotrophic molecules. Ann Neurol 1989, 26:486-506.
41. Beal MF, Brouillet E, Jenkins BG, Ferrante FJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hyman BT: Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurol 1993, 13:4181-4192.
42. Beal MF, Ferrante RJ, Swartz KJ, Kowall NW: Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J Neurosci 1991, 11:1649-1659.
43. Beal MF, Hyman BT, Koroschetz W: Do defects in mitochondria energy metabolism underlie the pathology of neurodegenerative diseases? TINS 1993, 16:125-131.
44. Emerich DF, Winn SR, Hantraye PM, Peschanski M, Chen E-Y, Chu Y, McDermott P, Baetge EE, Kordower JH: Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature 1997, 386:395-399. This study demonstrates the utility of biologically delivered CNTF as a neuroprotective agent in primates. When challenged by QA, GABAergic, cholinergic and diaphorase-positive neurons are protected from excitotoxic death.
45. Emerich DF, Lindner MD, Winn SR, Chen E-Y, Frydel BR, Kordower JH: Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease. J Neurol 1996, 16:5168-5181. In this study, CNTF-secreting fibroblasts are shown to attenuate QA-induced lesion size and behavioral abnormalities in rats.
46. Anderson KD, Panayotatos N, Corcoran TL, Lindsay RM, Wiegand SJ: Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington disease. Proc Natl Acad Sci U S A 1996, 93:7346-7351. Purified recombinant CNTF is shown to protect rat striatal neurons from excitotoxic degeneration. In contrast, purified NGF, BDNF, and neurotophin-3 fail to protect from death induced by intrastriatal injection of QA.
47. Frim DM, Uhler TA, Short MP, Ezzedine ZD, Klagsbrun M, Breakefield XO, Isacson O: Effects of biologically delivered NGF, BDNF and bFGF on striatal excitotoxic lesions. NeuroReport 1993, 4:367-370.
48. Schumacher JM, Short MP, Hyman BT, Breakefield XO, Isacson O: Interacerebral implantation of nerve growth factor-producing fibroblasts protects striatum against neurotoxic levels of exictatory amino acids. Neuroscience 1991, 45:561-570.
49. Frim DM, Simpson J, Uhler TA, Short MP, Bossi SR, Breakefield XO, Isacson O: Striatal degeneration induced by mitochondrial blockade is prevented by biologically delivered NGF. J Neurosc Res 1993, 35:452-458.
50. Emerich DF, Hammang JP, Baetge EE, Winn SR: Implantation of polymer-encapsulated human nerve growth factor-secreting fibroblasts attenuates the behavioral and neuropathological consequences of quinolinic acid injections into rodent striatum. Exp Neurol 1994, 130:141-150.
51. Martin SJ, Green DR: Protease activation during apoptosis: death by a thousand cuts? Cell 1995, 82:349-352.
52. Ellis HM, Horvitz HR: Genetic control of programmed cell death in the nematode Caenorhabditis elegans. Cell 1986, 44:817-829.
53. Yuan J-Y, Shaham S, Ledoux S, Ellis HJM, Horvitz HR: The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. Cell 1993, 75:641-652.
54. Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry NA, Wong WW, Yuan J: Human ICE/CED-3 protease nomenclature. Cell 1996, 87:171. This short paper describes the new nomenclature for the cysteinyl aspartic acid-specific proteases (caspases) involved in apoptosis. A dendogram showing the divisions of the caspases into subfamilies is provided.
55. Goldberg YP, Nicholson DW, Rasper DM, Kalchman MA, Koide HB, Graham RK, Gromm M, Kazemi-Esfarjani P, Thornberry NA, Vaillancourt JP, Hayden MR: Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nature Genet 1996, 13:442-449. The authors demonstrate that huntingtin is a kinetically relevant substrate for the apoptotic protease caspase 3 (apopain) in vitro and in vivo. Because there is a subtle increase in the rate of cleavage for huntingtin with long CAG tracts, this study suggests a possible link between CAG expansion and initiation of apoptosis.
56. Kuida K, Zheng TS, Na S, Kuan C-Y, Yang D, Karasuyama H, Rakic P, Flavell RA: Decreased apoptosis in the brain and premature lethality in CPP32-deflclent mice. Nature 1996, 384:368-372. This landmark study illustrates the crucial role for caspase 3 (apopain) in developmental neural apoptosis. The authors show that mice deficient in apopain have grossly abnormal neural ectopic masses that are large enough to cause secondary skull defects. Importantly, the overall neural organization of these ectopic masses appears normal.
57. Ikeda H, Yamaguchi M, Sugai S, Aze Y, Narumiya S, Kakizuka A: Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nature Genet 1996, 13:196-202. This intriguing study illustrates the ability of expanded polyglutamine tracts to result in apoptosis in cell culture and in vivo when targeted to Purkinje cells.
58. Onodera O, Roses AD, Tsuji S, Vance JM, Strittmatter WJ, Burke JR: Toxicity of expanded polyglutamine-domain proteins in Escherichia coli. FEBS Lett 1996, 399:135-139.